블로그

• Gastric Cancer News A patient information sheet has been published on the FDA Web site.[1] Sutent is an oral kinase inhibitor of fms-like tyrosine kinase 3 (Flt3), Kit, VEGF, and PDGF receptors that is currently in clinical trials blog.naver.com · 2006.11.26